Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial

被引：168

作者：

Huober, J. ^{[1
,5
]}

Fasching, P. A. ^{[2
,14
]}

Barsoum, M. ^{[3
]}

Petruzelka, L. ^{[4
]}

Wallwiener, D. ^{[5
]}

Thomssen, C. ^{[6
]}

Reimer, T. ^{[7
]}

Paepke, S. ^{[8
]}

Azim, H. A. ^{[9
]}

Ragosch, V. ^{[10
]}

Kubista, E. ^{[11
]}

Baumgaertner, A. K. ^{[8
]}

Beckmann, M. W. ^{[2
]}

May, C. ^{[12
]}

Nimmrich, I. ^{[12
]}

Harbeck, N. ^{[8
,13
]}

机构：

[1] Kantonsspital, Breast Ctr, CH-9007 St Gallen, Switzerland

[2] Univ Erlangen Nurnberg, Dept Gynaecol, D-91054 Erlangen, Germany

[3] Cairo Univ, Natl Canc Inst, Cairo, Egypt

[4] Univ Hosp Prague, Dept Oncol, Prague, Czech Republic

[5] Univ Tubingen, Dept Obstet & Gynaecol, Tubingen, Germany

[6] Univ Halle Wittenberg, Dept Gynaecol, Halle, Saale, Germany

[7] Univ Rostock, Dept Obstet & Gynaecol, Rostock, Germany

[8] Tech Univ Munich, Frauenklin Rechts Isar, Munich, Germany

[9] Cairo Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[10] Asklepios Klin Altona, Dept Gynaecol, Hamburg, Germany

[11] Med Univ Vienna, Dept Gynaecol, Vienna, Austria

[12] Novartis Pharrna GmbH BU Oncol, Nurnberg, Germany

[13] Univ Cologne, Breast Ctr, Dept OB&GYN, D-50931 Cologne, Germany

[14] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA

来源：

BREAST | 2012年 / 21卷 / 01期

关键词：

Metastatic breast cancer; Endocrine treatment; Letrozole; Trastuzumab; ADJUVANT CHEMOTHERAPY; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; TAMOXIFEN; HER-2/NEU; ARIMIDEX; SAFETY; PLUS; HER2;

D O I：

10.1016/j.breast.2011.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The eLEcTRA trial compared efficacy and safety of letrozole combined with trastuzumab to letrozole alone in patients with HER2 and hormone receptor (HR) positive metastatic breast cancer (MBC). Patients were randomized to either letrozole alone (arm A, n = 31) or letrozole plus trastuzumab (arm B, n = 26) as first-line treatment. Additional 35 patients with HER2 negative and HR positive tumors received letrozole alone (arm C). Median time to progression in arm A was 3.3 months compared to 14.1 months in arm B (hazard ratio 0.67; p = 0.23) and 15.2 months in arm C (hazard ratio 0.71; p = 0.03). Clinical benefit rate was 39% for arm A compared to 65% in arm B (odds ratio 2.99, 95% CI 1.01-8.84) and 77% in arm C (odds ratio 5.34, 95% CI 1.83-15.58). The eLEcTRA trial showed that the combination of letrozole and trastuzumab is a safe and effective treatment option for patients with HER2 positive and HR positive MBC. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：27 / 33

页数：7

共 27 条

[1] Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance [J].

Arpino, Grazia ;

Wiechmann, Lisa ;

Osborne, C. Kent ;

Schiff, Rachel .

ENDOCRINE REVIEWS, 2008, 29 (02) :217-233

[2] The cardiac safety of trastuzumab in the treatment of breast cancer [J].

Chien, A. Jo ;

Rugo, Hope S. .

EXPERT OPINION ON DRUG SAFETY, 2010, 9 (02) :335-346

[3] Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98 [J].

Coates, Alan S. ;

Keshaviah, Aparna ;

Thuerlimann, Beat ;

Mouridsen, Henning ;

Mauriac, Louis ;

Forbes, John F. ;

Paridaens, Robert ;

Castiglione-Gertsch, Monica ;

Gelber, Richard D. ;

Colleoni, Marco ;

Lang, Istvan ;

Del Mastro, Lucia ;

Smith, Ian ;

Chirgwin, Jacquie ;

Nogaret, Jean-Marie ;

Pienkowski, Tadeusz ;

Wardley, Andrew ;

Jakobsen, Erik H. ;

Price, Karen N. ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :486-492

[4] Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial [J].

Dowsett, Mitch ;

Allred, Craig ;

Knox, Jill ;

Quinn, Emma ;

Salter, Janine ;

Wale, Chris ;

Cuzick, Jack ;

Houghton, Joan ;

Williams, Norman ;

Mallon, Elizabeth ;

Bishop, Hugh ;

Ellis, Ian ;

Larsimont, Denis ;

Sasano, Hironobu ;

Carder, Pauline ;

Cussac, Antonio Llombart ;

Knox, Fiona ;

Speirs, Valerie ;

Forbes, John ;

Buzdar, Aman .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1059-1065

[5] Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial [J].

Ellis, MJ ;

Coop, A ;

Singh, B ;

Mauriac, L ;

Llombert-Cussac, A ;

Jänicke, F ;

Miller, WR ;

Evans, DB ;

Dugan, M ;

Brady, C ;

Quebe-Fehling, E ;

Borgs, M .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3808-3816

[6] First-select the target:: better choice of adjuvant treatments for breast cancer patients [J].

Goldhirsch, A. ;

Coates, A. S. ;

Gelber, R. D. ;

Glick, J. H. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2006, 17 (12) :1772-1776

[7] Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer [J].

Howell, A ;

Cuzick, J ;

Baum, M ;

Buzdar, A ;

Dowsett, M ;

Forbes, JF ;

Hoctin-Boes, G ;

Houghton, I ;

Locker, GY ;

Tobias, JS .

LANCET, 2005, 365 (9453) :60-62

[8] Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer [J].

Johnston, Stephen ;

Pippen, John, Jr. ;

Pivot, Xavier ;

Lichinitser, Mikhail ;

Sadeghi, Saeed ;

Dieras, Veronique ;

Gomez, Henry Leonidas ;

Romieu, Gilles ;

Manikhas, Alexey ;

Kennedy, M. John ;

Press, Michael F. ;

Maltzman, Julie ;

Florance, Allison ;

O'Rourke, Lisa ;

Oliva, Cristina ;

Stein, Steven ;

Pegram, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (33) :5538-5546

[9] Enhancing the Efficacy of Hormonal Agents with Selected Targeted Agents [J].

Johnston, Stephen R. D. .

CLINICAL BREAST CANCER, 2009, 9 :S28-S36

[10]

KAUFMAN B, 2006, EUR SOC MED ONC ESMO

← 1 2 3 →